||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models

InSphero AG /
InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

Comprehensive, customizable platforms for preclinical drug safety and efficacy
testing, coupled with emerging organ-on-a-chip technology, garner investor
support



Schlieren, Switzerland, June 13, 2018 (GLOBE NEWSWIRE) -- InSphero AG today
announced that it has raised USD 10 million in its latest funding round with
additional financing, secured from internal and external investors, bringing its
total funding to date to USD 35 million. An innovative provider of 3D cell-based
platforms for drug discovery and efficacy testing, InSphero will apply the funds
to further enhance its discovery platforms for metabolic diseases and cancer.

InSphero's comprehensive solutions for preclinical drug safety and efficacy
testing are based on 3D microtissues, which are phenotypic models of the
smallest functional unit of a tissue or organ. These drug-discovery and testing
platforms combine scalable 3D technology, ISO quality-controlled 3D human tissue
models, 3D-optimized media, as well as tailored assay services and support.
Drug-discovery partners immediately gain access to the depth and breadth of
InSphero's experience in developing and applying 3D models for liver
toxicology, metabolic diseases (e.g, T1 and T2 diabetes, and liver diseases
NAFLD and NASH), and oncology.

A new milestone for the market leader is the successful linking of different 3D
microtissues through a unique microfluidic organ-on-a-chip technology that
enables researchers to better understand how drugs affect the human body as a
whole. The technology is used in ongoing research collaborations with academic
and industry partners, such as Roche Pharmaceuticals in Basel, Switzerland, and
the Swiss Federal Institute of Technology (ETH). The technology,
baptized Akura(TM) Flow, promises to transform drug discovery and development,
with the potential to make animal testing in pharma and cosmetic companies
obsolete.

InSphero CEO and co-founder Dr. Jan Lichtenberg says, "This funding will enable
us to complete our transition from a supplier to a partner, offering our
customers the full value of our 3D technology and knowledge of applied 3D
disease modeling-whether they need a complex custom model, a body-on-a-chip
system, or an experienced collaborator for a long-term, joint discovery
project."

Former GM of Promega Switzerland Dr. Jürg Gysi, who is now President of the
InSphero Board of Directors and an investor in this round, adds, "Over the past
several years, InSphero has created tangible benefits for pharma and biotech
companies worldwide. This secured funding will support the company's continuing
growth, which was exceeding 40% in the second half of 2017 alone."

InSphero has received ongoing fundraising support from Venturelab, which has
nurtured their evolution from a Swiss start-up to a global biotechnology leader,
with customers from all top ten pharmaceutical companies.

For more information about InSphero, visit www.insphero.com.



###

InSphero contacts

Dr. Frank Junker
Chief Business Officer
Phone +41 44 5150490
frank.junker@insphero.com

Dr. Jan Lichtenberg
Chief Executive Officer
Phone +41 44 5150490
jan.lichtenberg@insphero.com

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the
pharmaceutical and biotechnology industry with comprehensive solutions that
provide greater confidence in decision making. Its robust and highly
physiologically relevant suite of 3D InSight(TM) Platforms are used by major
pharmaceutical companies worldwide to increase efficiency in drug discovery and
safety testing. The company specializes in liver toxicology, metabolic diseases
(e.g, T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a
focus on immuno-oncology and PDX models). 3D InSight(TM) Discovery and Safety
Platforms are used by all top 10 pharmaceutical companies and are available in
96-well, 384-well, and organ-on-a-chip formats to drive efficient innovation
throughout all phases of drug development.


For more information, visit www.insphero.com.

Follow us on Twitter and LinkedIn.



Attachment

* Logo ohne Tagline_ISGreen_RGB

Karen Dowell
InSphero AG
800-779-7558
karen.dowell@insphero.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: InSphero AG via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.073 Sekunden